NanoViricides CEO, Eugene Seymour, MD, MPH, Invited to Discuss the Current Ebola Outbreak on Fox Bus. News at 9PM EDT Tonight
October 07 2014 - 1:56AM
Business Wire
NanoViricides, Inc. (NYSE MKT:NNVC) (the “Company”), a
nanomedicine company developing anti-viral drugs, reported that its
CEO, Eugene Seymour, MD, MPH, has been invited to discuss the
current Ebola outbreak and the Company’s progress on a novel
experimental Ebola drug on “The Independents”, a show on the Fox
Business News Channel (FBN) tonight at 9PM EDT.
He will discuss some of the difficulties that could be
encountered in attempts to bring the Ebola epidemic under control.
Dr. Seymour has extensive field experience in the area of
infectious diseases. He has previously worked
on HIV/AIDS in Africa, Eastern Europe and Asia. D.
Seymour was interviewed on FBN regarding the Ebola crisis earlier
on September 16th.
The Company has now developed novel nanoviricide drug candidates
against Ebola that it believes could lead to a successful
therapeutic. These drug candidates are designed to mimic the host
cell receptor onto which the Ebola virus binds to cause an
infection. The site at which the virus binds does not change, in
spite of all the mutations a virus undergoes. Thus the Company
believes that its drug candidates would continue to work in spite
of field mutations in the virus. This is unlike vaccines,
antibodies, siRNA, antisense, and several other therapeutic modes
which a virus can readily overcome due to mutations it acquires in
the field.
The Company had previously developed anti-Ebola drug candidates
that demonstrated the validity and potential of the Company’s
approach, based on cell culture and animal testing conducted at US
Army Medical Research Institute of Infectious Diseases (USAMRIID)
in a BSL-4 facility. The Company had to de-prioritize this
development in order to focus on the development of its lead drug
candidate, Injectable FluCide™, for treatment of hospitalized
patients with influenza. The Company has recently reported that it
has restarted its anti-Ebola/Marburg drug program, in consideration
of the severe public health impact of an Ebola virus epidemic. The
current outbreak in Africa has unequivocally demonstrated the need
for an effective, broad-spectrum, anti-Ebola therapeutic.
The Company is in negotiations with several parties regarding
testing the new nanoviricide drug candidates against Ebola in the
required high safety environments, i.e. BSL-4 facilities.
NanoViricides, Inc. now has the capability of producing
sufficient quantities of an anti-Ebola drug, after it is developed,
for combating current and future Ebola epidemics. The highly
customizable nanomedicine cGMP capable pilot scale manufacturing
facility in Shelton, CT, will be able to supply all of the
nanoviricides drug candidates in quantities needed for human
clinical trials.
As of October 1, 2014, the World Health Organization (WHO) and
the Centers for Disease Control (CDC) reported a total of
approximately 7,493 suspected cases and 3,439 deaths, with the Case
Fatality Rate (CFR) standing at 70%, derived using data from
patients with definitive clinical outcomes, according to Wikipedia
(http://en.wikipedia.org/wiki/Ebola_virus_epidemic_in_West_Africa).
Unfortunately, this Ebola outbreak has continued to expand at an
exponential rate in spite of significant efforts to contain it. It
has also continued to spread geographically. A first case of Ebola
infection detected in the USA occurred in Dallas, TX, recently,
with the patient who flew in from Liberia while having no symptoms.
The first confirmed case of Ebola infection contracted outside of
Africa has occurred in Spain in a nurse, who was taking care of two
volunteer priests that became infected with Ebola virus and were
brought back from Africa, at the Hospital Carlos III in Madrid.
Currently, there are no approved drugs or vaccines against
Ebola, , although some vaccines as well as some drug candidates
have entered clinical trials. Recently, WHO has announced a policy
for use of experimental drugs against Ebola to expedite drug
availability.
About NanoViricides:
NanoViricides, Inc. (www.nanoviricides.com) is a development stage company that is creating
special purpose nanomaterials for viral therapy. The Company's
novel nanoviricide® class of drug candidates are designed to
specifically attack enveloped virus particles and to dismantle
them. The Company is developing drugs against a number of viral
diseases including H1N1 swine flu, H5N1 bird flu, seasonal
Influenza, HIV, oral and genital Herpes, viral diseases of the eye
including EKC and herpes keratitis, Hepatitis C, Rabies, Dengue
fever, and Ebola virus, among others.
This press release contains forward-looking statements that
reflect the Company's current expectation regarding future events.
Actual events could differ materially and substantially from those
projected herein and depend on a number of factors. Certain
statements in this release, and other written or oral statements
made by NanoViricides, Inc. are “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933 and
Section 21E of the Securities Exchange Act of 1934. You should not
place undue reliance on forward-looking statements since they
involve known and unknown risks, uncertainties and other factors
that are, in some cases, beyond the Company's control and which
could, and likely will, materially affect actual results, levels of
activity, performance or achievements. The Company assumes no
obligation to publicly update or revise these forward-looking
statements for any reason, or to update the reasons actual results
could differ materially from those anticipated in these
forward-looking statements, even if new information becomes
available in the future. Important factors that could cause actual
results to differ materially from the company's expectations
include, but are not limited to, those factors that are disclosed
under the heading "Risk Factors" and elsewhere in documents filed
by the company from time to time with the United States Securities
and Exchange Commission and other regulatory authorities. Although
it is not possible to predict or identify all such factors, they
may include the following: demonstration and proof of principle in
pre-clinical trials that a nanoviricide is safe and effective;
successful development of our product candidates; our ability to
seek and obtain regulatory approvals, including with respect to the
indications we are seeking; the successful commercialization of our
product candidates; and market acceptance of our products.
NanoViricides, Inc.Anil Diwan, 203-937-6137info@nanoviricides.com
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Mar 2024 to Apr 2024
NanoViricides (AMEX:NNVC)
Historical Stock Chart
From Apr 2023 to Apr 2024
